...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in drug safety. >Applicability of EU(7)-PIM criteria in cross-national studies in European countries
【24h】

Applicability of EU(7)-PIM criteria in cross-national studies in European countries

机译：欧盟（7） - 欧洲国家跨国研究标准的适用性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.
机译：欧洲联盟（欧盟）（7）-PIM（潜在不恰当的药物）列表列举了评估欧洲PIM的最全面和最新的工具;然而，一些国家特定的研究已经记录了一些国家的本名单的特异性。我们的研究目的是描述欧盟（7）-PIM标准的PIMS批准率和营销[与美国老年人（AGS）2015年标准相比]。六个欧盟国家（捷克共和国，西班牙，葡萄牙，塞尔维亚，塞尔维亚，匈牙利和土耳其）研究团队参加了由WG1B欧盟成本行动为1402集团2015年10月至2015年10月期间进行的这项研究。关于PIMS批准及其可用性的数据在制药市场上已从国家药物监管机构和最新药物培养的数据库中获得。欧盟（7）-PIM列表和AGS啤酒2015年标准（第1节）进行了应用。来自欧盟（7）-PIM列表的PIM批准用于临床使用，而不是来自AGS BEERS 2015年度标准的临床用途（第1节）。欧盟（7）的批准率 - 西班牙的42.8％，西班牙的71.4％（仅适用于AGS标准，分别从36.4％到65.1％）。在西班牙（71.4％），葡萄牙（67.1％）和土耳其（67.5％），匈牙利（55.5％），捷克共和国（50.2％）和塞尔维亚（42.8％）较低，批准的PIM百分比较高百分比。大多数批准的PIM批准的PIM也被销售在除土耳其（19.8-21.7％而非销售PIM）之外的所有国家销售，并且少于20％的PIMS可作为柜台的药物提供（土耳其除外，46.4-48.1％除外） 。欧盟（7）-PIM清单是在欧洲研究中使用的利用;然而，在一些国家仍然有限，特别是在东部和中欧的适用性。欧盟项目Euroageism H2020（2017-2021）专注于在中欧和东欧国家的PIM规定和监管措施必须考虑这些限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号